Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

SutroVax

SutroVax
2013 FOUNDED
PRIVATE STATUS
Series D LATEST DEAL TYPE
$110M LATEST DEAL AMOUNT
14 INVESTORS
Description

Developer of conjugate and novel complex antigen-based vaccines intended to prevent serious infectious diseases. The company's cell-free protein synthesis platform permits site-specific conjugation, enabling the creation of conjugate vaccines with the potential to deliver heightened immunity and broader protection.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Primary Office
  • 353 Hatch Drive
  • Foster City, CA 94404
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore SutroVax’s full profile, request a free trial.

SutroVax Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 26-Mar-2020 $110M 00000 Completed Startup
5. Later Stage VC (Series C) 19-May-2018 0000 00000 00000 Completed Startup
4. Early Stage VC (Series B) 21-Mar-2017 0000 000.00 00000 Completed Pre-Clinical Trials
3. Grant 01-Jan-2016 00000 000.00 Completed Startup
2. Early Stage VC (Series A) 23-Jul-2015 $26.3M $24.3M 000.00 Completed Startup
1. Seed Round 08-Jan-2014 $2M $2M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

SutroVax Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.00
Series A 00,000,000 00.000000 00.0 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

SutroVax Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inhibrx Venture Capital-Backed La Jolla, CA 00 000.00 00000000
000000000000 Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
0000000 0000000000 Formerly VC-backed Berkeley, CA 000 00000 00000000 00000
000000 Formerly PE-Backed Paris, France 00 000.00 000000000 000.00
000000 Angel-Backed Lyon, France 00 00.000 0000000000 00.000
To view this company’s complete list of competitors, request access »

SutroVax Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Janus Henderson Investors Hedge Fund Minority 000 0000 000000 0
RA Capital Management Venture Capital Minority 000 0000 000000 0
Foresite Capital Management Growth/Expansion Minority 000 0000 000000 0
Medicxi Venture Capital Minority 000 0000 000000 0
TPG Growth PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

SutroVax Executive Team (9)

Name Title Board
Seat
Contact
Info
Grant Pickering Co-Founder, President, Chief Executive Officer, Director & Board Member
Jeff Fairman Ph.D Co-Founder & Vice President of Research
Jim Wassil Chief Operating Officer
Paul Sauer Vice President, Process Development & Manufacturing
Aron Stein Ph.D Vice President, Regulatory Affairs and Quality Assurance

3 Former Executives

You’re viewing 5 of 9 executives. Get the full list »

SutroVax Board Members (17)

Name Representing Role Since Contact
Info
Agustin Mohedas Ph.D Janus Henderson Investors Board Observer 000 0000
Cristina Ghenoiu Ph.D Longitude Capital Board Observer 000 0000
Derek DiRocco Ph.D RA Capital Management Board Observer 000 0000
Francesco De Rubertis Ph.D Medicxi Board Observer 000 0000
Grant Pickering SutroVax Co-Founder, President, Chief Executive Officer, Director & Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 17 board members. Get the full list »